Sotrovimab (VIR 7831) is a monoclonal antibody against the SARS-CoV-2 virus that causes COVID-19. It has antiviral activity, induces serum neutralization of BQ.1 and antibody-dependent cytotoxicity, and may be used to study viral infections.

SARS-CoV-2 Delta:51.3 ng/mL, SARS-CoV-2 Kappa:118.64 ng/mL, SARS-CoV-2 Alpha:187.2 ng/mL, SARS-CoV-2 Beta:71.9 ng/mL, SARS-CoV-2 Gamma:73.11 ng/mL

Sotrovimab neutralizes SARS-CoV-2 and SARS-CoV but does not directly block viral receptor binding. Sotrovimab injected into the culture medium for 200 seconds at a concentration of 100 μg/mL (flow rate of 30 μL/min) was effective in binding to the surface-expressed SARS-CoV-2 S protein.Sotrovimab treated for 30 minutes at concentrations ranging from 0.3 ng/mL to 20 mg/mL exhibited in vitro neutralization of SARS-CoV-2 pseudotyped virus, and in vitro neutralization of Alpha, Beta, Gamma, and SARS-CoV. Sotrovimab exhibited in vitro neutralization of SARS-CoV-2 pseudotyped virus at concentrations ranging from 0.3 ng/mL to 20 mg/mL for 30 min, with IC50 values of 187.2 ng/mL, 71.9 ng/mL, 73.11 ng/mL, 51.3 ng/mL, and 118.64 ng/mL for the Alpha, Beta, Gamma, Delta, and Kappa variant viruses, respectively. [1][2]

Sotrovimab was able to provide protective exposure to susceptible variants in the lungs of female crab-eating monkeys for up to 28 days after a single dose of 5 mg/kg (10 mL) was administered via intravenous catheter. [2]